LAKESHORE BIOPHARMA CO., LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6977 USD | +0.93% |
|
-8.20% | +36.54% |
| Jun. 10 | Lakeshore Biopharma Co., Ltd Announces Executive Changes | CI |
| May. 28 | YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS | CI |
Valuation
| Fiscal Period: Marzo | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,022 | 953.4 | - | - |
| Enterprise Value (EV) 1 | 1,022 | 953.4 | 953.4 | 953.4 |
| P/E ratio | -7.04 x | -1.59 x | -4.64 x | 5.01 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 1.6 x | 1.15 x | 0.69 x |
| EV / Revenue | - | 1.6 x | 1.15 x | 0.69 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 93,058 | 188,328 | - | - |
| Reference price 2 | 10.99 | 5.062 | 5.062 | 5.062 |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | 596.2 | 826.7 | 1,387 |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -351.7 | -139.9 | 85.51 |
| Operating Margin | - | -59% | -16.93% | 6.17% |
| Earnings before Tax (EBT) 1 | - | -299 | -123.9 | 116 |
| Net income 1 | -283.5 | -297 | -121.5 | 118.4 |
| Net margin | - | -49.81% | -14.7% | 8.54% |
| EPS 2 | -1.560 | -3.190 | -1.090 | 1.010 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 176.3 | 96.82 | 165 | 158.1 | 175.8 | 185.3 | 199.8 | 230.1 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -113.2 | -81.67 | -49.44 | - | - | - | - |
| Operating Margin | - | -116.92% | -49.5% | -31.28% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -105.2 | -85.21 | -55.94 | - | - | - | - |
| Net income 1 | - | -105 | -77.77 | -55.34 | - | - | - | - |
| Net margin | - | -108.43% | -47.14% | -35.01% | - | - | - | - |
| EPS 2 | - | -1.130 | -0.8300 | -0.5900 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 8/16/23 | 1/22/24 | 4/19/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 7/26/23 | - | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.062
CNY
Average target price
29.98
CNY
Spread / Average Target
+492.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.54% | 131M | |
| +0.75% | 92.38B | |
| -3.03% | 37.9B | |
| -10.46% | 33.73B | |
| +74.08% | 27.98B | |
| -13.39% | 15.86B | |
| -1.08% | 13.97B | |
| -11.15% | 11.67B | |
| +169.04% | 10.17B | |
| -50.19% | 10.04B |
- Stock Market
- Equities
- LSB Stock
- Financials LakeShore Biopharma Co., Ltd
